872 related articles for article (PubMed ID: 21278589)
1. Long-term effect of BAK-free travoprost on ocular surface and intraocular pressure in glaucoma patients after transition from latanoprost.
Aihara M; Otani S; Kozaki J; Unoki K; Takeuchi M; Minami K; Miyata K
J Glaucoma; 2012 Jan; 21(1):60-4. PubMed ID: 21278589
[TBL] [Abstract][Full Text] [Related]
2. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
Aihara M; Oshima H; Araie M;
Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
[TBL] [Abstract][Full Text] [Related]
3. Duration of IOP reduction with travoprost BAK-free solution.
Gross RL; Peace JH; Smith SE; Walters TR; Dubiner HB; Weiss MJ; Ochsner KI
J Glaucoma; 2008; 17(3):217-22. PubMed ID: 18414108
[TBL] [Abstract][Full Text] [Related]
4. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
[TBL] [Abstract][Full Text] [Related]
5. Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study.
Lopes JF; Hubatsch DA; Amaris P
BMC Ophthalmol; 2015 Nov; 15():166. PubMed ID: 26563363
[TBL] [Abstract][Full Text] [Related]
6. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Uusitalo H; Chen E; Pfeiffer N; Brignole-Baudouin F; Kaarniranta K; Leino M; Puska P; Palmgren E; Hamacher T; Hofmann G; Petzold G; Richter U; Riedel T; Winter M; Ropo A
Acta Ophthalmol; 2010 May; 88(3):329-36. PubMed ID: 20546237
[TBL] [Abstract][Full Text] [Related]
7. Ocular surface tolerability of prostaglandin analogs and prostamides in patients with glaucoma or ocular hypertension.
Crichton AC; Vold S; Williams JM; Hollander DA
Adv Ther; 2013 Mar; 30(3):260-70. PubMed ID: 23475405
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma.
Gandolfi S; Paredes T; Goldberg I; Coote M; Wells A; Volksone L; Pillai MR; Stalmans I; Denis P;
Eur J Ophthalmol; 2012; 22(1):34-44. PubMed ID: 22167541
[TBL] [Abstract][Full Text] [Related]
9. Ocular surface tolerability of prostaglandin analogs in patients with glaucoma or ocular hypertension.
Whitson JT; Trattler WB; Matossian C; Williams J; Hollander DA
J Ocul Pharmacol Ther; 2010 Jun; 26(3):287-92. PubMed ID: 20578283
[TBL] [Abstract][Full Text] [Related]
10. A 6-week, double-masked, parallel-group study of the efficacy and safety of travoprost 0.004% compared with latanoprost 0:005%/timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension.
Franks WA; Renard JP; Cunliffe IA; Rojanapongpun P
Clin Ther; 2006 Mar; 28(3):332-9. PubMed ID: 16750448
[TBL] [Abstract][Full Text] [Related]
11. Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy.
Lewis RA; Katz GJ; Weiss MJ; Landry TA; Dickerson JE; James JE; Hua SY; Sullivan EK; Montgomery DB; Wells DT; Bergamini MV;
J Glaucoma; 2007 Jan; 16(1):98-103. PubMed ID: 17224758
[TBL] [Abstract][Full Text] [Related]
12. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%.
Maul E; Carrasco FG; Costa VP; Casiraghi JF; Vargas E; Sarmina JS; Mayol R
Clin Ther; 2007 Sep; 29(9):1915-23. PubMed ID: 18035191
[TBL] [Abstract][Full Text] [Related]
13. Polyquaternium-1-Preserved Travoprost 0.003% or Benzalkonium Chloride-Preserved Travoprost 0.004% for Glaucoma and Ocular Hypertension.
Peace JH; Ahlberg P; Wagner M; Lim JM; Wirta D; Branch JD
Am J Ophthalmol; 2015 Aug; 160(2):266-274.e1. PubMed ID: 25935098
[TBL] [Abstract][Full Text] [Related]
14. Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears.
Kahook MY; Noecker RJ
Cornea; 2008 Apr; 27(3):339-43. PubMed ID: 18362664
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines.
Stewart WC; Konstas AG; Nelson LA; Kruft B
Ophthalmology; 2008 Jul; 115(7):1117-1122.e1. PubMed ID: 18082886
[TBL] [Abstract][Full Text] [Related]
16. Circadian IOP-lowering efficacy of travoprost 0.004% ophthalmic solution compared to latanoprost 0.005%.
García-Feijoo J; Martínez-de-la-Casa JM; Castillo A; Méndez C; Fernández-Vidal A; García-Sánchez J
Curr Med Res Opin; 2006 Sep; 22(9):1689-97. PubMed ID: 16968572
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
Kanamoto T; Kiuchi Y; Tanito M; Mizoue S; Naito T; Teranishi S; Hirooka K; Rimayanti U;
J Ocul Pharmacol Ther; 2015 Apr; 31(3):156-64. PubMed ID: 25710276
[TBL] [Abstract][Full Text] [Related]
18. From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability.
Rossi GC; Scudeller L; Rolle T; Pasinetti GM; Bianchi PE
Expert Opin Drug Saf; 2015 May; 14(5):619-23. PubMed ID: 25759110
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma.
Rouland JF; Traverso CE; Stalmans I; Fekih LE; Delval L; Renault D; Baudouin C;
Br J Ophthalmol; 2013 Feb; 97(2):196-200. PubMed ID: 23203707
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of latanoprost, travoprost, and bimatoprost on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
Orzalesi N; Rossetti L; Bottoli A; Fogagnolo P
Ophthalmology; 2006 Feb; 113(2):239-46. PubMed ID: 16458092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
